US Biosimilar Market – Who's In It For The Long Haul?
Executive Summary
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
You may also be interested in...
AAM's Francer Talks Quality, Pricing And Biosimilars
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Generics Bulletin sister publication Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
Strides Plans Re-Entry On Injectables
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.